Protox Therapeutics Inc. (“Protox”, TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced that it has entered into a US $15 million loan agreement ...

Canada's Protox Therapeutics has landed a $75 million development and commercialization agreement with Japan-based Kissei Pharmaceutical. The $75 million deal covers PRX302, Protox's PSA-activated pro ...

VANCOUVER, Oct. 8 /CNW/ - Protox Therapeutics Inc. (TSX: PRX - News), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its Phase 1 study of ...

For the remainder of the year, Protox expects to continue to incur costs related to the further clinical, manufacturing and regulatory activities associated with its PRX302 BPH program. At June 30, ...

Shareholders of Vancouver-based Protox Therapeutics Inc. (TSX:PRX) have approved multi-stage financing that could see a global private equity firm become the company’s majority shareholder. Under the ...

Warburg Pincus to become co's largest shareholder Says to finance clinical activities for BPH treatment Protox shares up 14 pct Warburg Pincus members to assume Protox chairmanship Sept 29 (Reuters) - ...

VANCOUVER – Protox Therapeutics Inc. (TSX:PRX), a developer of drugs to treat urological diseases, said Monday it has entered into a US $15 million loan agreement with a U.S. lender to help the ...

VANCOUVER , Jan. 11 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded ...

It's not easy keeping a poker face. I mean there are so many times when I meet people and it would be beneficial to keep a straight face, but sometimes it's just so hard! When a patient tells me they ...